What is the project?
Immunoscape™ is a sophisticated immune mapping platform developed by Verily that combines laboratory phenotyping and advanced computational analysis techniques to generate detailed profiles of the immune system. Verily and Gilead are employing this platform to understand inflammatory autoimmune diseases at a high degree of molecular resolution.
How are you making it happen?
The Immunoscape platform represents the next-generation of tools to understand the immune system, harnessing the latest in genomic and immunologic laboratory technologies and leveraging Verily’s ability to curate and analyze health data at scale. Verily’s vision for Immunoscape is to create a comprehensive molecular map of diseases with inflammatory pathogenesis, beginning with this project with Gilead and expanding to other diseases. Verily is working together with Gilead to deploy the Immunoscape platform to derive deep insights from biological samples collected from patients participating in Gilead clinical trials for therapies of three common and serious inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases. This collaboration represents the broadest effort to-date to interrogate the activity of specific subtypes of immune cells to better understand disease signatures and treatment response. Immunoscape analysis will create a deeper understanding of the biological mechanisms of immune dysfunction that underpin these conditions, which may result in improved therapeutic management of patients.